Financial Performance - Operating revenue for the reporting period was ¥1,409,780,106.36, representing a year-on-year growth of 4.78%[7] - Net profit attributable to shareholders was ¥29,820,609.37, a significant increase of 627.77% compared to the same period last year[7] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥52,833,013.16, up by 209.62% year-on-year[7] - Basic earnings per share for the reporting period was ¥0.0361, reflecting a growth of 646.97% compared to the same period last year[7] - The company's net profit margin improved, with retained earnings increasing to CNY 1,299,618,263.38 from CNY 1,016,631,127.91, a growth of approximately 28%[34] - Net profit for the current period reached ¥88,606,875.33, compared to ¥7,363,804.29 in the previous period, marking an increase of 1,103.5%[48] - The profit margin improved, with operating profit rising to ¥29,246,346.91 from a loss of ¥7,214,666.96[40] - The company reported a total comprehensive income of ¥50,495,374.60, recovering from a loss of ¥8,284,851.17 in the previous period[42] Assets and Liabilities - Total assets at the end of the reporting period reached ¥7,879,029,850.54, an increase of 6.51% compared to the end of the previous year[7] - Total liabilities amounted to CNY 5,525,126,485.84, compared to CNY 5,069,751,005.31, showing an increase of around 9%[34] - Current liabilities rose to CNY 4,322,569,309.96, compared to CNY 3,867,420,027.56, indicating an increase of about 11.8%[34] - Short-term borrowings increased significantly to CNY 2,536,522,088.21 from CNY 1,994,564,062.70, reflecting a rise of approximately 27.3%[34] - The total current assets reached ¥3.70 billion, up from ¥2.82 billion at the end of 2018, indicating a growth of about 30.8%[31] - The company's equity totaled CNY 2,327,809,913.03, with total equity attributable to shareholders at CNY 2,320,169,647.84[64] Cash Flow - Cash flow from operating activities for the year-to-date reached ¥50,523,434.72, an increase of 227.85%[7] - The net cash flow from operating activities for Q3 2019 was ¥50,523,434.72, a significant improvement compared to a net outflow of ¥39,519,112.25 in the same period last year[55] - Total cash inflow from operating activities amounted to ¥4,278,980,722.62, while cash outflow was ¥4,228,457,287.90, resulting in a net increase of ¥50,523,434.72[55] - The company reported a net cash flow from financing activities of ¥68,365,778.14, compared to a net inflow of ¥431,984,667.72 in the previous year[56] Shareholder Information - The total number of shareholders at the end of the reporting period was 45,884[11] - The largest shareholder, Jiangyin Mould Group Co., Ltd., held 35.78% of the shares, amounting to 295,959,745 shares[11] - The company has committed to fulfilling all promises made to minority shareholders in a timely manner, demonstrating a commitment to corporate governance[27] Investments and Projects - The new factory project in Shenyang is set to invest a total of ¥500 million, with a registered capital of ¥29.99 million[17] - The company is focusing on expanding its market presence and enhancing its product offerings through ongoing research and development initiatives[34] - Research and development expenses were ¥43,365,135.06, slightly down from ¥47,679,046.09, indicating a focus on cost management[40] Financial Management - The company reported no significant non-recurring gains or losses that would affect the financial results[8] - The company has no overdue amounts or risks associated with entrusted financial management, indicating a stable financial position[23] - There were no derivative investments during the reporting period, reflecting a conservative investment strategy[23] - The company executed new financial accounting standards starting January 1, 2019, affecting the reporting of financial instruments[68] Operational Highlights - The supply qualification rate for the U.S. factory reached 85%, exceeding the initial target of 80%[16] - The Wuxi Mingci Cardiovascular Hospital reported a 62% increase in medical revenue to ¥66.47 million, with outpatient visits rising by 92%[18] - The company plans to expand its orthopedic services, with preparations nearing completion for a launch before the New Year[19]

Financial Performance - The company's operating revenue for the first half of 2019 was CNY 2,523,583,288.30, representing an increase of 11.99% compared to CNY 2,253,396,030.03 in the same period last year[17]. - The net profit attributable to shareholders of the listed company reached CNY 59,583,122.28, a significant increase of 349.47% from CNY 13,256,204.73 in the previous year[17]. - Basic and diluted earnings per share were both CNY 0.0720, reflecting a growth of 350.00% from CNY 0.0160 in the previous year[17]. - The operating profit for the same period was CNY 82.23 million, reflecting a significant growth of 81.82% compared to the previous year[37]. - The company reported a net cash flow from operating activities of -RMB 9,121,038.90, a significant decrease of 107.77% from RMB 117,353,585.72 in the previous year[41]. - The company achieved a revenue of RMB 2,523,583,288.30 in the first half of 2019, representing an increase of 11.99% compared to RMB 2,253,396,030.03 in the same period last year[41]. - The company reported a net profit for the first half of 2019 of CNY 59,050,313.38, significantly higher than CNY 13,014,059.24 in the first half of 2018, marking a growth of 354.36%[149]. - The company’s total comprehensive income for the period was CNY 85,725,998.22, contrasting with a loss of CNY 98,198,736.13 in the same period of 2018[153]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 7,709,082,705.12, an increase of 4.21% from CNY 7,397,560,918.34 at the end of the previous year[17]. - The company's total liabilities increased to CNY 5,298,593,706.21 from CNY 5,069,751,005.31, reflecting a rise of about 4.5%[142]. - The company's equity attributable to shareholders increased to CNY 2,403,381,542.62 from CNY 2,320,169,647.84, representing a growth of approximately 3.6%[142]. - The company's total liabilities increased to CNY 4,780,655,340.40 from CNY 4,344,417,323.59, representing a rise of 10.05%[146]. - The total liabilities at the end of the period were 4,000 million yuan, maintaining a balanced financial structure[166]. Investments and R&D - The company’s investment in research and development rose by 13.21% to RMB 93,292,140.10 compared to RMB 82,406,137.13 in the previous year[41]. - The company has a strong focus on R&D, enhancing product and service quality, and deepening cooperation with premium clients such as BMW and Volvo[37]. - The company reported an investment income of CNY 96,638,663.34, compared to CNY 74,643,508.69 in the previous year, showing a growth of 29.41%[149]. Market and Operations - The company is actively expanding its market presence, particularly in the new energy vehicle sector and overseas markets, to enhance its market share[37]. - The company has established a modern cardiovascular specialty hospital, Mingci Hospital, which integrates advanced German medical management and technology[34]. - The company has established a quality management system compliant with ISO/TS16949, ensuring high product quality and efficient production operations[31]. - The company has a total of 69.35 million RMB in securities investments, with a fair value of approximately 470.84 million RMB at the beginning of the period[52]. Cash Flow and Financing - The cash flow from operating activities showed a net outflow of CNY 9,121,038.90, a decline from a net inflow of CNY 117,353,585.72 in the previous year[155]. - The company’s cash flow from financing activities generated a net inflow of CNY 125,895,957.36, down from CNY 490,152,709.29 in the first half of 2018[156]. - The company utilized 184.13 million RMB of idle raised funds to temporarily supplement working capital, which has since been fully returned[124]. Corporate Governance and Compliance - The company plans not to distribute cash dividends or issue bonus shares[6]. - The company has not engaged in any significant asset or equity sales during the reporting period[54][55]. - The company’s half-year financial report has not been audited[69]. - There were no major litigation or arbitration matters during the reporting period[71]. Social Responsibility and Environmental Impact - The company is involved in social responsibility initiatives, including improving cardiovascular treatment levels in impoverished areas[95]. - The company has conducted environmental impact assessments for new projects, including a new automotive color bumper painting production line[93]. - The company reported a total wastewater discharge of 131,400 tons per year, with no exceedance of discharge standards[91]. Shareholder Information - The company’s largest shareholder, Jiangyin Mould Group Co., Ltd., holds 35.78% of the total shares, with 54,985,337 shares under limited sale conditions[111]. - The company’s total share capital increased to 827,181,434 shares after a reduction of 21,000 shares due to bond conversion[107]. - The company’s total number of ordinary shareholders at the end of the reporting period was 39,294[111].

江南模塑科技股份有限公司 2019 年第一季度报告全文 股票代码：000700 股票简称：模塑科技 公告编号：2019-026 债券代码：127004 债券简称：模塑转债 江南模塑科技股份有限公司 2019 年第一季度报告 2019 年 04 月 1 江南模塑科技股份有限公司 2019 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人曹克波、主管会计工作负责人曹克波及会计机构负责人(会计主管人员)钱建 芬声明：保证季度报告中财务报表的真实、准确、完整。 2 | 项目 | 年初至报告期期末金额 | 说明 | | --- | --- | --- | | 非流动资产处置损益（包括已计提资产减值准备的冲销部分） | -13,260.75 | | | 计入当期损益的政府补助（与企业业务密切相关，按照国家统 | 86,000.00 | | | 一标准定额或定量享受的政府补助除外） | | | | 除同公司正常经营业务相关的有效 ...

Financial Performance - The company's operating revenue for 2018 was approximately ¥4.97 billion, representing a 14.41% increase compared to ¥4.34 billion in 2017[16] - The net profit attributable to shareholders for 2018 was approximately ¥11 million, a significant decrease of 91.82% from ¥134 million in 2017[16] - The net cash flow from operating activities was negative at approximately ¥14.65 million, a decline of 119.24% compared to a positive cash flow of ¥76.14 million in 2017[16] - The basic earnings per share for 2018 was ¥0.012, down 92.64% from ¥0.163 in 2017[16] - Total assets at the end of 2018 were approximately ¥7.40 billion, a decrease of 1.79% from ¥7.53 billion at the end of 2017[17] - The net assets attributable to shareholders decreased by 13.71% to approximately ¥2.32 billion from ¥2.69 billion in 2017[17] - The company reported a net profit attributable to shareholders after deducting non-recurring gains and losses of approximately -¥154.94 million for 2018[16] - The weighted average return on net assets for 2018 was 0.41%, down from 4.12% in 2017[17] Revenue Breakdown - Total revenue for 2018 reached ¥4,965,647,396.78, representing a year-on-year increase of 14.41% compared to ¥4,340,149,793.15 in 2017[49] - Revenue from automotive decorative parts accounted for 95.62% of total revenue, with a year-on-year growth of 14.15% to ¥4,748,084,742.11[49] - Medical service revenue surged by 50.59% to ¥62,974,140.74, up from ¥41,818,155.28 in 2017[49] Investment and Expansion - The company has entered the healthcare industry with the opening of Wuxi Mingci Hospital in 2016, diversifying its business into automotive parts and healthcare[14] - The company successfully launched its US factory in 2018 and is set to commence operations in Mexico in 2019, marking a significant step towards internationalization[33] - The company has implemented a strategy focused on "large scale, low cost, and high speed" to enhance operational efficiency through lean production management[26] - The company plans to increase R&D investment and expand market share in 2019, focusing on sustainable development and diversification into the healthcare sector[45] Operational Challenges - The company reported a decrease in inventory levels by 10.46%, with total inventory at 1,119,000 units[52] - Operating cash inflow totaled ¥4,446,467,667.89, an increase of 10.93% year-over-year due to a 14.41% increase in sales revenue[60] - Operating cash outflow amounted to ¥4,461,120,554.38, up 13.46% year-over-year primarily due to increased procurement costs, with operating costs rising by 18.33%[60] - Net cash flow from operating activities was negative at ¥-14,652,886.49, a decline of 119.24% year-over-year attributed to increased losses from overseas factories[60] Shareholder Returns - The company plans to distribute a cash dividend of ¥1.30 per 10 shares (including tax) to all shareholders[4] - The cash dividend represents 977.71% of the net profit attributable to ordinary shareholders for the year[102] - The company has maintained a consistent cash dividend policy over the past three years, with dividends of CNY 1.20 per 10 shares in 2017 and CNY 1.10 in 2016[99][100] Corporate Governance - The company maintained a strict governance structure in accordance with relevant laws and regulations, ensuring no significant discrepancies with the guidelines set by the China Securities Regulatory Commission[193] - The company operates independently from its controlling shareholder in terms of business, personnel, assets, organization, and finance, with a clear and complete business system[195] - Independent directors attended all required board meetings and shareholder meetings, demonstrating active engagement in corporate governance[197] Social Responsibility and Environmental Compliance - The company emphasizes its commitment to social responsibility, ensuring accurate and timely information disclosure to shareholders[142] - The company actively participates in public welfare activities, including medical assistance for heart disease patients in various regions[142] - The company has implemented wastewater treatment facilities and RTO incineration systems for air pollution control, ensuring compliance with emission standards[149] Research and Development - R&D expenses increased by 16.73% to ¥194,965,287.95, representing 3.93% of total revenue, up from 3.85% in 2017[58] - The number of R&D personnel rose by 11.92% to 432, increasing the proportion of R&D staff to 11.89% of total employees[58] - The company will increase R&D investment, particularly in new products and processes, to meet stringent technical requirements from major automotive manufacturers[87]

江南模塑科技股份有限公司 2018 年第三季度报告正文 证券代码：000700 证券简称：模塑科技 公告编号：2018-100 江南模塑科技股份有限公司 2018 年第三季度报告正文 1 江南模塑科技股份有限公司 2018 年第三季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人曹克波、主管会计工作负责人曹克波及会计机构负责人(会计主 管人员)钱建芬声明：保证季度报告中财务报表的真实、准确、完整。 2 江南模塑科技股份有限公司 2018 年第三季度报告正文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 √ 是 □ 否 追溯调整或重述原因 同一控制下企业合并 | | 本报告期末 | 上年度末 | | 本报告期末比上年度 | | --- | --- | --- | --- | --- | | | | | | 末增减 | | | | 调整前 | 调整后 | 调整后 | | 总资产（ ...

江南模塑科技股份有限公司 2018 年半年度报告全文 | 证券代码：000700 | 证券简称：模塑科技 | 公告编号：2018-087 | | --- | --- | --- | | 债券代码：127004 | 债券简称：模塑转债 | | 江南模塑科技股份有限公司 2018 年半年度报告 2018 年 08 月 1 江南模塑科技股份有限公司 2018 年半年度报告全文 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 公司负责人曹克波、主管会计工作负责人曹克波及会计机构负责人(会计主 管人员)钱建芬声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本半年度报告涉及未来计划等前瞻性陈述，不构成公司对投资者的实质承 诺，请投资者注意投资风险。 公司在本报告第四节"经营情况讨论与分析"中"十、公司面临的风险和应对 措施"部分，详细描述了公司经营中可能存在的风险及应对措施，敬请投资者关 注相关内容。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 第一节 ...

江南模塑科技股份有限公司 2018 年第一季度报告正文 | 股票代码：000700 | 股票简称：模塑科技 | 公告编号：2018-049 | | --- | --- | --- | | 债券代码：127004 | 债券简称：模塑转债 | | 江南模塑科技股份有限公司 2018 年第一季度报告正文 1 江南模塑科技股份有限公司 2018 年第一季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人曹克波、主管会计工作负责人曹克波及会计机构负责人(会计主 管人员)钱建芬声明：保证季度报告中财务报表的真实、准确、完整。 2 江南模塑科技股份有限公司 2018 年第一季度报告正文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 √ 是 □ 否 追溯调整或重述原因 同一控制下企业合并 | | 本报告期 | 上年同期 | | 本报告期比上年同 | | --- | --- | --- | -- ...

江南模塑科技股份有限公司 2017 年年度报告全文 股票代码：000700 股票简称：模塑科技 公告编号：2018-030 债券代码：127004 债券简称：模塑转债 江南模塑科技股份有限公司 2017 年年度报告 2018 年 04 月 1 江南模塑科技股份有限公司 2017 年年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连 带的法律责任。 公司负责人曹克波、主管会计工作负责人曹克波及会计机构负责人(会计主 管人员)钱建芬声明：保证年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本年度报告涉及未来计划等前瞻性陈述，不构成公司对投资者的实质承诺， 请投资者注意投资风险。 公司在本报告第四节"经营情况讨论与分析"中"十、公司面临的风险和应对 措施"部分，详细描述了公司经营中可能存在的风险及应对措施，敬请投资者关 注相关内容。 公司经本次董事会审议通过的利润分配预案为：以 827,178,715 为基数，向 全体股东每 10 股派发现金红利 1.2 ...

Financial Performance - Operating revenue for the period was CNY 846,399,489.31, representing a 4.06% increase year-on-year[8] - Net profit attributable to shareholders decreased by 7.67% to CNY 48,309,716.47 compared to the same period last year[8] - Net profit attributable to shareholders after deducting non-recurring gains and losses fell by 18.40% to CNY 12,990,623.43[8] - Basic earnings per share decreased by 7.67% to CNY 0.0674[8] - Diluted earnings per share decreased by 7.26% to CNY 0.0677[8] - Weighted average return on equity decreased by 0.41 percentage points to 1.53%[8] Cash Flow and Assets - Cash flow from operating activities decreased by 81.72% to CNY 53,645,358.00 year-to-date[8] - Cash and cash equivalents increased by 48.27% to ¥97,712.90 million due to the arrival of convertible bond funds[16] - The net cash flow from operating activities decreased by 82% to ¥5,365 million, primarily due to payments of initial payables[16] - The net cash flow from investing activities worsened by 148% to -¥78,640 million, reflecting increased investments in overseas projects in the US and Mexico[16] - The net cash flow from financing activities surged by 768% to ¥106,252 million, driven by increased financing for projects in the US and Mexico[16] - Total assets increased by 14.49% to CNY 6,794,270,135.29 compared to the end of the previous year[8] Shareholder Information - The company had a total of 47,586 shareholders at the end of the reporting period[12] - The largest shareholder, Jiangyin Mould Group Co., Ltd., holds 33.07% of the shares, amounting to 237,153,488 shares[12] Investments and Acquisitions - The company plans to invest an additional $49.5 million in its wholly-owned subsidiary MingHua USA Inc., raising the total investment to $99.5 million[20] - The company is in the process of acquiring 100% equity of DaDa Decoration through a share and cash transaction, with a 60% and 40% split in total consideration[17] - The company received approval from the China Securities Regulatory Commission for its asset acquisition application, indicating regulatory compliance[19] - The company holds investments in various stocks, with a total initial investment of approximately ¥28 million in Jiangnan Water Affairs, valued at ¥371.73 million at the beginning of the period[25] - The fair value of the company's investment in Jiangsu Bank was approximately ¥967.26 million, with a reported loss of ¥1.74 million during the period[25] Operational Highlights - The company has completed 143 heart surgeries and 263 cardiovascular procedures at Wuxi Mingci Hospital, significantly increasing the surgical volume compared to the previous year[21] - The company is progressing on overseas projects, with equipment commissioning expected by the end of 2017 for the US project and early 2019 for the Mexico project[20] Regulatory and Compliance - There were no instances of non-compliance with external guarantees during the reporting period[29] - The company reported no non-operational fund occupation by controlling shareholders or related parties during the reporting period[30] - There were multiple inquiries from individuals regarding the company's performance forecasts and asset acquisition progress throughout the reporting period[27][28] Other Information - The company has not engaged in any derivative investments during the reporting period[26] - The company has not conducted any poverty alleviation work or announced future plans for such initiatives during the third quarter[31] - The company reported a potential significant change in cumulative net profit for the year, indicating possible losses compared to the previous year[24] - The company reported a 456.75% increase in other current assets, primarily due to increased deductible VAT in Mexico[16]

江南模塑科技股份有限公司 2017 年半年度报告全文 江南模塑科技股份有限公司 2017 年半年度报告 2017 年 08 月 1 江南模塑科技股份有限公司 2017 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 公司负责人曹克波、主管会计工作负责人曹克波及会计机构负责人(会计主 管人员)钱建芬声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本半年度报告涉及未来计划等前瞻性陈述，不构成公司对投资者的实质承 诺，请投资者注意投资风险。 公司在本报告第四节"经营情况讨论与分析"中"十、公司面临的风险和 应对措施"部分，详细描述了公司经营中可能存在的风险及应对措施，敬请投 资者关注相关内容。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | 第一节 | 重要提示、目录和释义 | 2 | | --- | --- | --- | | 第二节 | 公司简介和主要财务指标 | 5 | | 第三节 | 公司业 ...